INCY Initiates Coverage On Bernstein -- Rating Set to Market Per
Bernstein has initiated coverage on Incyte (INCY) with a "Market Perform" rating and a price target of $99.00. GuruFocus indicates that INCY is slightly undervalued by 1.9% with a GF Value of $99.05, and boasts a strong GF Score of 89/100 due to robust financial strength and momentum. Despite this, there has been significant insider selling totaling $4.98 million over the past three months, with no reported insider purchases.
Bernstein initiates Incyte stock coverage with concerns on growth
Bernstein SocGen Group initiated coverage on Incyte Corp. (NASDAQ:INCY) with a Market Perform rating and a $99.00 price target, citing concerns about revenue growth post-Jakafi's loss of exclusivity in 2028. The firm believes Incyte's current life cycle management efforts are insufficient to replace Jakafi's revenue, though early-stage drug candidate INCA033989 is seen as the best opportunity for future growth.
Bernstein initiates Incyte stock coverage with concerns on growth By Investing.com
Bernstein SocGen Group initiated coverage on Incyte Corp. (NASDAQ: INCY) with a Market Perform rating and a price target of $99, citing concerns about revenue growth after the loss of exclusivity for its key drug, Jakafi, in 2028. Jakafi currently accounts for 60% of Incyte’s fiscal 2025 revenue, and the firm believes Incyte’s current life cycle management efforts are insufficient to offset the projected decline. While the company has a strong balance sheet and is exploring new drug candidates like INCA033989, Bernstein awaits further trial details to assess its potential as a significant growth catalyst.
Bernstein initiates Incyte stock coverage with concerns on growth
Bernstein SocGen Group initiated coverage on Incyte Corp. (NASDAQ:INCY) with a Market Perform rating and a $99.00 price target, citing concerns over future revenue growth after Jakafi's patent expiry in 2028. Jakafi currently accounts for a significant portion of Incyte's revenue, and Bernstein believes the company's current life cycle management efforts are insufficient to fully replace the projected revenue decline. The firm highlighted the early-stage drug candidate INCA033989 as a key opportunity for future growth.
Incyte Insider Sold Shares Worth $1,423,950, According to a Recent SEC Filing
An insider at Incyte Corporation (NASDAQ: INCY) recently sold shares valued at $1,423,950, as disclosed in a recent SEC filing. This transaction occurred on May 21, 2026, and was reported by MT Newswires.
Incyte (NASDAQ: INCY) director exercises options and sells 15K shares
Incyte director Paul J. Clancy exercised non-qualified stock options for 15,000 shares at $84.53 each and simultaneously sold these 15,000 shares at $94.93 per share in an open-market transaction on May 19, 2026. Following these transactions, Clancy directly holds 23,741 common shares, which includes 2,518 shares from unvested restricted stock units. This activity is characterized as a routine exercise-and-sell, resulting in a net reduction of his direct share ownership.
How Incyte’s (INCY) Opzelura Data and Edison AI Deal Could Reframe Its Risk Profile
Incyte's recent developments, including new 24-week Phase 3b data for Opzelura in moderate atopic dermatitis and an AI collaboration with Edison Scientific, aim to reduce its reliance on Jakafi. These advancements support pipeline diversification, though the company still faces challenges from Jakafi's patent overhang and potential margin compression if new product launches underperform. Investors should consider these factors in conjunction with projected revenue and earnings growth, as analysts have varying outlooks for Incyte's future performance.
Incyte Corp stock (US45337C1027): focus on latest Jakafi data and pipeline outlook
Incyte Corp remains a significant player in the biopharmaceutical industry, with its flagship drug Jakafi driving a major portion of its revenue. The company is actively investing in a broad and costly clinical pipeline, particularly in hematology-oncology and immunology, which makes its future growth highly dependent on successful trial readouts and regulatory approvals. Investors are advised to monitor Jakafi's performance, late-stage clinical milestones, and competitive product developments to assess Incyte's long-term revenue and market position.
Incyte expands AI drug discovery pact with $120M funding boost
Incyte has expanded its collaboration with an AI drug discovery partner, committing an additional $120 million. This increased funding demonstrates Incyte's continued investment in artificial intelligence to accelerate the discovery and development of new therapeutic compounds. The partnership aims to leverage AI's capabilities for more efficient and effective drug development.
Incyte Grants Equity Awards to New CFO Suketu Upadhyay
Incyte Corporation has granted equity inducement awards to its new Executive Vice President and CFO, Suketu Upadhyay, as part of his employment agreement. These awards, issued under the company's 2024 Inducement Stock Incentive Plan, include stock options, restricted stock units, and performance share awards. The compensation package is tied to Incyte's closing stock price on May 4, 2026, and its vesting is contingent on Upadhyay's continued employment and the company's performance.
Inside Incyte’s $120 Million AI For Drug Development Deal
Incyte has signed a $120 million deal with Genesis Molecular AI for drug development, involving $80 million upfront and a $40 million equity investment, with potential for over $1 billion in milestone payments and royalties. This partnership integrates Incyte's proprietary data with Genesis's AI model to accelerate drug discovery across various therapeutic areas. Meanwhile, Apnimed has filed for regulatory approval for a sleep apnea drug, and Isomorphic Labs continues to raise significant capital for its AI-driven drug development efforts, focusing on an internal pipeline.
Incyte (INCY) CMO granted 44,124 performance-based shares in Form 4/A
Incyte's Chief Medical Officer, Steven H. Stein, was granted 44,124 performance-based shares after the compensation committee confirmed the achievement of specified development, revenue, and market-based goals. These shares, part of an amended Form 4/A filing, will vest on the third anniversary of the July 14, 2023 grant date, contingent on his continued employment. Following this, Stein holds 78,327 unvested shares from RSUs and earned performance shares.
Incyte (NASDAQ: INCY) awards 31,517 earned performance shares to R&D president
Incyte (NASDAQ: INCY) has awarded President and Global Head of R&D Pablo J. Cagnoni 31,517 earned performance shares. These shares, granted on May 6, 2026, are subject to vesting on the third anniversary of the original July 14, 2023 grant date, provided he remains with the company. The number of shares Cagnoni can ultimately receive ranges from 0% to 150% based on development, revenue, and market-based goals tied to the Nasdaq Biotechnology Index.
iShares U.S. Pharmaceuticals ETF outperforms despite drug pricing policy risks, up 38% in 12 months.
The iShares U.S. Pharmaceuticals ETF (IHE) has significantly outperformed over the past year, gaining 38% despite potential negative impacts from U.S. drug pricing policies. This success is attributed to strong dividend yields and robust drug pipelines from major holdings like Eli Lilly and Johnson & Johnson, particularly due to GLP-1 drug advancements. While attractive for investors near retirement, the ETF has concentration risk and faces policy uncertainties.
Incyte Corp. stock outperforms competitors on strong trading day
Incyte Corp. (INCY) stock rose 1.55% to $97.08 on Wednesday, outperforming the broader market as the S&P 500 Index and Dow Jones Industrial Average also saw significant gains. This marks the second consecutive day of increases for the stock.
Incyte (INCY) Expands AI Drug Discovery Partnership with Genesis Molecular AI
Incyte (INCY) has expanded its AI drug discovery partnership with Genesis Molecular AI, investing $120 million to leverage Genesis' GEMS platform for accelerating small-molecule drug development. This collaboration includes at least five new drug targets and grants Incyte exclusive development and commercialization rights. Despite recent insider selling, Incyte holds a strong GF Score of 89/100, boasts robust financial health, and its P/E ratio suggests a potentially undervalued stock.
Incyte and Genesis expand molecular ai collaboration to accelerate drug discovery
Incyte Corporation and Genesis have expanded their molecular AI collaboration to accelerate drug discovery. This partnership aims to leverage artificial intelligence to enhance the efficiency and speed of developing new therapeutic products, particularly for cancers and inflammatory disorders. The article notes that the pharma sector is increasingly adopting AI to potentially reduce costs and timelines in drug development.
Q4 2025 Incyte Corp Earnings Call Transcript
Incyte Corp (INCY) reported strong financial results for Q4 and full-year 2025, exceeding expectations in sales and advancing multiple assets into late-stage development. The company saw a 28% increase in fourth-quarter revenue to $1.51 billion and a 21% increase in full-year revenue to $5.14 billion. While facing competitive challenges and regulatory hurdles, Incyte is focused on continued growth, especially with the promising pediatric launch of Opsilor AD in the US.
Drugmaker Incyte pours $120M into AI to speed search for new medicines
Incyte (Nasdaq: INCY) has significantly expanded its collaboration with Genesis Molecular AI, investing $120 million to accelerate drug discovery using AI. This partnership focuses on leveraging Incyte's proprietary experimental data to train Genesis's GEMS AI platform for identifying novel molecules, aiming to speed up the development of new medicines across multiple programs. The deal includes upfront payments, equity purchase, recurring research funding, and potential milestone payments and royalties for Genesis, which could exceed $1 billion for the initial five collaboration targets.
Prelude Therapeutics (Nasdaq:PRLD) - Stock Analysis
This extensive analysis of Prelude Therapeutics (PRLD) covers its stock performance, financial health, and pipeline developments. The company, a clinical-stage precision oncology firm, is currently unprofitable but forecasts strong revenue growth. Recent updates include positive preclinical data for PRT13722 in breast cancer and FDA clearance for PRT12396 in myeloproliferative neoplasms, alongside ongoing shareholder dilution and share price volatility.
Number of shareholders of Incyte Corporation – MIL:1INCY
The article provides a title "Number of shareholders of Incyte Corporation – MIL:1INCY" but no actual content regarding the number of shareholders. It appears to be a stub or an incomplete data listing from TradingView for Incyte Corporation. The rest of the page is filled with navigation links and footer information from the TradingView platform.
[144] INCYTE CORP SEC Filing
This article details an Incyte Corp (INCY) SEC Form 144 filing, indicating a proposed sale of 15,000 shares of common stock by an individual through Morgan Stanley Smith Barney LLC. The shares were acquired via a stock option exercise on May 19, 2026, with an aggregate market value of $1,424,005.50. The filing reports no other securities sold in the past three months and includes standard legal disclaimers regarding material adverse information.
Inside the AI 'scientist' Incyte will use to guide drug research
Incyte (Nasdaq: INCY) has announced a strategic collaboration with Edison Scientific to integrate Edison's Kosmos AI platform into its drug discovery and development processes. The AI scientist, Kosmos, will continuously learn from translational and clinical data to inform experimental design and improve decision-making across Incyte's R&D organization, starting with target discovery and translational biology. This partnership aims to enhance the quality and speed of drug development by making Incyte's data a "compounding asset" that systematically improves outcomes over time.
Incyte Stock: Analyst Estimates & Ratings
Incyte Corporation (INCY) has outperformed the broader market over the past year, with its shares soaring 49.2%, though it is down 3.6% year-to-date. The biopharmaceutical company recently posted stronger-than-expected Q1 results, with revenue up 20.9% and adjusted EPS of $1.81. Analysts maintain a "Moderate Buy" consensus rating for INCY, with a mean price target suggesting a 16.4% premium to current levels.
Between Incyte and Regeneron Pharmaceuticals, Which Stock Looks Set to Break Out?
This article compares Incyte (INCY) and Regeneron Pharmaceuticals (REGN), suggesting Incyte as the more attractive investment. Incyte shows superior revenue growth, higher operating margins, and a lower valuation compared to Regeneron. Historical market performance data also indicates that Incyte has delivered better returns and higher monthly win rates.
Incyte Corp stock (US45337C1027): Institutional buying draws fresh attention to the biotech group
Incyte Corp has garnered fresh attention from investors after Northwestern Mutual Wealth Management significantly increased its stake in the biotech company by over 5,000% during the fourth quarter. The company, which specializes in oncology and inflammation therapies, relies on its flagship product Jakafi and a robust pipeline for revenue growth. This institutional interest highlights Incyte's position as a mid-cap biopharmaceutical company balancing established commercial products with ongoing innovation.
Incyte Corporation (INCY) Stock Analysis: Insight into Potential 13.84% Upside in the Biotech Sector
Incyte Corporation (INCY) shows a potential 13.84% upside with an average analyst target price of $108.50, driven by its robust product pipeline including JAKAFI and ICLUSIG, and strategic collaborations. The company, valued at $19.04 billion, demonstrates strong financial health with 20.90% revenue growth and a 30.82% return on equity. While analyst sentiment is balanced, Incyte's focus on innovative therapeutics and reinvestment in R&D makes it an attractive option for investors in the biotech sector.
Incyte Corporation $INCY Shares Purchased by Northwestern Mutual Wealth Management Co.
Northwestern Mutual Wealth Management Co. significantly increased its stake in Incyte Corporation (NASDAQ:INCY) by 5,218.5% in Q4, acquiring 585,618 additional shares. This move contributed to institutional investors now owning 96.97% of the company's stock. Incyte also reported strong quarterly earnings, surpassing analyst expectations with $1.81 EPS and $1.27 billion in revenue, although Wall Street maintains a "Hold" rating with an average price target of $104.26.
Ruxolitinib Market 2026-2033 | Market Growth to Fiscal Year (Q2) - Incyte. Novartis AG.
The Ruxolitinib Market is projected for significant growth from 2026-2033, driven by strategic initiatives from major players like Incyte and Novartis AG. The market, valued at US$ 5.24 billion in 2024 and projected to reach US$ 6.3 billion by 2027, is expanding due to increasing demand, technological advancements, and a growing application scope across various indications. North America leads the market, while Asia-Pacific is the fastest-growing region, fueled by rising awareness and investments in healthcare.
Arrowhead Licenses ARO PNPLA3 To Madrigal To Expand MASH Options
Arrowhead Pharmaceuticals has licensed its ARO-PNPLA3 RNAi therapeutic to Madrigal Pharmaceuticals for the development and commercialization of treatments for MASH. This agreement, which includes potential milestone and royalty revenues, allows Arrowhead to advance its RNAi platform in liver and metabolic diseases without bearing the full cost of late-stage development. The deal highlights Arrowhead's strategy of leveraging partnerships for non-dilutive capital and expanded market access, while also presenting both risks and rewards for investors regarding profitability and competition.
Free cash flow per share of Incyte Corporation – BX:ICY
This article provides financial information for Incyte Corporation (ICY) on BX Swiss, specifically focusing on its free cash flow per share. The content includes a brief overview of the company's financials for different periods, along with the value and percentage change of its free cash flow per share.
Incyte Corp. stock underperforms Friday when compared to competitors
Incyte Corp. (INCY) stock fell 2.38% on Friday, closing at $95.31, underperforming the broader market. This marked the fourth consecutive day of losses for the company, as the S&P 500 Index dropped 1.24% and the Dow Jones Industrial Average declined 1.07%.
Arbejdsmarkedets Tillaegspension Purchases Shares of 244,419 Incyte Corporation $INCY
Arbejdsmarkedets Tillaegspension initiated a new position in Incyte Corporation during the fourth quarter, acquiring 244,419 shares valued at approximately $24.1 million, representing 0.12% of the company. Incyte reported strong quarterly results with EPS of $1.81 and revenue of $1.27 billion, exceeding analyst estimates, although the stock was down 1.2% on Friday. The overall analyst consensus for Incyte remains a "Hold" with an average price target of $104.26, despite some recent upgrades and price target adjustments.
HCW Biologics Stock News: Profit, Pipeline and Nasdaq Risk Put HCWB Back in Focus
HCW Biologics (NASDAQ:HCWB) reported a first-quarter profit of $3.47 million, driven primarily by a $6.54 million licensing agreement with Trimmune Biotech in China for HCW11-006. Despite this temporary financial boost, the company faces significant challenges including an uncertain Nasdaq listing due to its stock trading below the $1 minimum, and substantial doubt about its ability to continue operations given its low cash reserves and history of net losses. HCW is awaiting preliminary Phase 1 trial results for its autoimmune candidate HCW9302 and is progressing with preclinical studies for HCW11-040 for bronchopulmonary dysplasia.
Goldman Sachs initiates Prelude Therapeutics stock coverage as Early-Stage Biotech
Goldman Sachs has initiated coverage of Prelude Therapeutics Inc. (NASDAQ:PRLD) with an "Early-Stage Biotech" rating. The clinical-stage company, which develops cancer medicines, has seen its stock gain 377% over the past year and possesses over $10 billion in potential unadjusted peak sales for its lead metastatic breast cancer program. Upcoming milestones include an IND filing and Phase 1 initiation in mid-to-late 2026, with an opt-in decision for another key asset by February 2027.
Working capital per share of Incyte Corporation – FWB:ICY
This page provides financial data specifically focusing on the working capital per share for Incyte Corporation (FWB:ICY). It highlights the company's financial overview, including historical values and changes in working capital per share, within the context of the Frankfurt Stock Exchange.
Edesa Biotech Advances on Two Fronts, Tackling Vitiligo and ARDS
Edesa Biotech is making significant progress in its dual pipeline, focusing on treatments for vitiligo and Acute Respiratory Distress Syndrome (ARDS). The company is preparing for a Phase 2 clinical study for EB06 in vitiligo and has reported positive Phase 3 data for paridiprubart in ARDS, despite climbing R&D expenses. These advancements aim to address unmet medical needs in both dermatology and critical care.
Dodge & Cox holds 12.25M Incyte shares (NASDAQ: INCY), a 6.2% stake
Dodge & Cox has reported a beneficial ownership of 12,252,356 shares in Incyte Corporation (NASDAQ: INCY), which represents a 6.2% stake in the company. This disclosure, made via a Schedule 13G/A SEC filing, indicates that Dodge & Cox holds sole voting power over 11,646,204 shares and sole dispositive power over all 12,252,356 shares on behalf of its clients. The filing clarifies that this is a passive investment and does not suggest an intent to control or influence the issuer.
Incyte Corp stock (US45337C1027): Biopharma leader in oncology therapies
Incyte Corporation is a biopharmaceutical company focused on oncology and inflammation treatments, with a market capitalization of $19.74 billion. The company exhibits strong financial performance with a P/E ratio of 13.96 and net margins of 26.71%, driven by its oncology product pipeline. Institutional ownership and a Nasdaq listing position Incyte as a significant player for US investors looking for growth in the biotechnology sector.
Incyte Corp. stock underperforms Thursday when compared to competitors
Incyte Corp. (INCY) stock fell 1.20% on Thursday, closing at $97.63, despite a positive trading session for the broader market. This marks the third consecutive day of losses for the company's stock. The S&P 500 Index and Dow Jones Industrial Average both saw gains.
Swiss Life Asset Management Ltd Boosts Stake in Incyte Corporation $INCY
Swiss Life Asset Management Ltd increased its stake in Incyte Corporation by 12.8% in the fourth quarter of the previous year, now holding 96,463 shares valued at approximately $9.53 million. This increase follows Incyte's strong quarterly earnings report, where it surpassed analyst expectations with an EPS of $1.81 and a 20.9% year-over-year revenue growth. Despite a mixed "Hold" rating from analysts, some firms have recently raised their price targets for the biopharmaceutical company.
Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Prelude Therapeutics reported its first-quarter 2026 financial results, highlighting the advancement of PRT12396 into Phase 1 studies for polycythemia vera and myelofibrosis, and plans to file an IND for PRT13722, a KAT6A degrader, by mid-2026. The company appointed Charles Morris, M.D., as Chief Medical Officer and extended its cash runway into the second quarter of 2028 following a $90 million underwritten offering. Net loss decreased to $10.4 million from $32.1 million in the prior year, driven by lower R&D and G&A expenses.
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress
Incyte announced that over 20 abstracts from its Hematology and Oncology programs have been accepted for presentation at the European Hematology Association (EHA) 2026 Congress. Key presentations include data from the pivotal Phase 3 frontMIND trial for tafasitamab in diffuse large B-cell lymphoma, supporting regulatory applications, and new data for INCA033989 for myeloproliferative neoplasms. This highlights the ongoing advancement and breadth of Incyte's pipeline in developing therapies for cancer and hematologic diseases.
Incyte Corp. stock underperforms Tuesday when compared to competitors
Incyte Corp. (INCY) shares decreased by 1.19% on Tuesday, closing at $99.13. This underperformance occurred on a mixed trading day where the Dow Jones Industrial Average rose, but the S&P 500 Index fell. The stock's decline ended a two-day winning streak.
Incyte details 20+ EHA 2026 abstracts, Phase 3 DLBCL data | INCY Stock News
Incyte announced that over 20 abstracts from its Hematology and Oncology programs, including results from the pivotal Phase 3 frontMIND trial for tafasitamab in diffuse large B-cell lymphoma (DLBCL), will be presented at the European Hematology Association (EHA) 2026 Congress. The frontMIND trial data has been selected for a prestigious Plenary Abstracts Session, supporting regulatory applications for tafasitamab. Additionally, new data for INCA033989 in myeloproliferative neoplasms (MPNs) will be featured in oral and poster presentations, highlighting the steady advancement of this molecularly targeted therapy.
Prelude Therapeutics Reports Q1 2026 Results, Advances Precision Oncology Pipeline and Extends Cash Runway to 2028
Prelude Therapeutics announced its Q1 2026 financial results, highlighting significant progress in its precision oncology pipeline, including the initiation of a Phase 1 study for PRT12396 and an upcoming IND filing for PRT13722. The company also reported a major decrease in net loss, with an extended cash runway into Q2 2028 following a $90 million offering. These developments position Prelude for several potential price-sensitive catalysts in the near future.
Prelude Therapeutics Inc 1Q 2026: Revenue $4.58M, EPS $(0.13) — 10-Q Summary
Prelude Therapeutics Inc. (PRLD) announced its first-quarter 2026 results, reporting revenue of $4.58 million and a net loss of $(0.13) per share, significantly improved from the prior year. This financial improvement was primarily driven by upfront option-related revenue from a partnership with Incyte. The company also highlighted clinical progress with its JAK2V617F inhibitor, advancements in its pipeline, and an approximately $90 million equity raise to secure funding for at least 12 months.
Incyte Corporation (INCY) Highlights Sustained Efficacy of Opzelura Through Week 24
Incyte Corporation (INCY) announced sustained efficacy of its drug Opzelura through Week 24 in a Phase 3 study for atopic dermatitis, with strong clinical responses maintained over time. The company also received FDA approval for Jakafi XR, an extended-release formulation extending dosing convenience for various hematologic and immune-related conditions. Incyte, a biopharmaceutical company, focuses on oncology, hematology, and inflammation with key drug Jakafi.
Incyte Corp. stock outperforms competitors on strong trading day
Incyte Corp. (INCY) shares rose 1.79% to $100.32, outperforming the broader market on a strong trading day. The S&P 500 Index increased by 0.19% and the Dow Jones Industrial Average also gained 0.19%. This marks the second consecutive day of gains for Incyte Corp. stock.
Incyte Corporation (INCY) Highlights Sustained Efficacy of Opzelura Through Week 24
Incyte Corporation reported sustained efficacy for its drug Opzelura in adults with moderate atopic dermatitis through Week 24 of the Phase 3 TRuE-AD4 study. Earlier treatment benefits were maintained, showing consistent improvements in skin involvement and itch control, with no new safety concerns. Additionally, the company received FDA approval for Jakafi XR, an extended-release formulation of ruxolitinib, offering a more convenient once-daily dosing regimen for various hematologic and immune-related conditions.
